TOP > 外国特許検索 > NOVEL CANCER MARKER AND UTILIZATION THEREOF

NOVEL CANCER MARKER AND UTILIZATION THEREOF UPDATE 新技術説明会 実績あり

外国特許コード F140007959
整理番号 S2013-0014-C0
掲載日 2014年9月26日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2013JP076123
国際公開番号 WO 2014061419
国際出願日 平成25年9月26日(2013.9.26)
国際公開日 平成26年4月24日(2014.4.24)
優先権データ
  • 特願2012-230245 (2012.10.17) JP
発明の名称 (英語) NOVEL CANCER MARKER AND UTILIZATION THEREOF UPDATE 新技術説明会 実績あり
発明の概要(英語) Provided is a novel cancer marker that is useful for the diagnosis of urothelial cancer. According to the present invention, ubiquilin 2 is used as a cancer marker for urothelial cancer (renal pelvic cancer, ureteral cancer, bladder cancer). By detecting ubiquilin 2 in a urine sample, the risk of urothelial cancer can be easily and exactly diagnosed. The present invention is also applicable to the diagnosis of squamous cancer (esophageal cancer, cervical cancer, etc.).
従来技術、競合技術の概要(英語) BACKGROUND ART
Urothelial cancer (renal pelvis cancer, urinary tract cancer, and bladder cancer) for the diagnosis of, the ureter and the radiation image diagnosis using a cystoscope or a mirror is the pathological tissue of the lesion were taken largely based on the diagnosis. However, the former radiation image diagnosis is non-invasive diagnosis method, the non - invasive detection of tumors is difficult, and the calculus or inflammatory lesions of the cancer is difficult to meet the problem. On the other hand, in the latter the pathological tissue diagnosis, while having high diagnostic accuracy, invasive method is, for an endoscope is inserted into the urethra, the pain given to the patient is large. Find an endoscope and a diseased tissue, since this must be collected, the operation of the endoscope for the determination of the lesion tissue and considerable skill is required. And an endoscopic is inserted into the body as well, and finally if the diseased tissue can be found, cannot be performed and accurate diagnosis.
Therefore, the urothelial cancer ('urinary system tumor' may be referred to.) Is a clinical assay, the less invasive nature are extremely important in the position of the urine cytology has been developed. Urine cytology is, the appearance in the urine of cancer cells was observed to method of diagnosing. Urine cytology for the diagnosis of various cells including, for example as described in Non-Patent Document 1-3.
Urine cytology is, naturally the patient's urine discharged from a test sample, for a so-called non-invasive diagnosis, without the pain for the patient. Can be readily obtained in the form of a sample, the inspection can be performed many times. However, in urine cytology, is small or when the number of cells in the sample, an allogeneic poor cancer cells is limited and the determination of a cell, a cancer cell in a determination of whether or not the considerable skill is required. Therefore, is small or when the number of cells in the sample, and determine the malignant cell morphology of a margin in the case where, even though the cancer, cancer in the diagnosis it may not. In addition, a different-normal cells by inflammation or indicate, in consideration of the reactivity of the cancer is renal tubular epithelial cells appear to indicate the more confusing or that a releasing. For this reason, in spite of the absence of the cancer cells, cancer cells which may cause the diagnosis. Therefore, the current urinary cytology, high specificity (cancer cells even though there is a lower probability of diagnosis of a cancer) but, in a diagnostic accuracy (sensitivity) is a fatal problem that is low is called. Further urine is used as a sample in cytological diagnosis easily be denatured in a urine sample, handling of the urine specimen is not accurate diagnosis is conducted.
Therefore, the patient's pain free non-invasive, high accuracy of the diagnosis and urothelial cancer diagnostic system development is demanded. In addition, cancer markers useful in cancer diagnosis However, the urothelial cancer marker effective for the diagnosis of cancer is not yet to be discovered.
The inventors of the present invention, the urothelium far conducted studies of molecular pathology of cancer, urothelial cancer cells (i), reactive oxygen species (ROS) different from normal cells to produce an excessive amount, labeling the ROS (ii), can be distinguished from cancer cells from normal cells was found (see Non-Patent Document 4.).
Incidentally, while the muscular strength is gradually decline, ultimately leading to paralysis systemic sclerosis (Amyotrophic lateral sclerosis and amyotrophic lateral sclerosis: ALS) is, when an abnormality occurs due to the 2 yubikirin has been demonstrated (see Non-Patent Document 5.). 2 Is this yubikirin, the defect or damage in the nerve cells of the protein is responsible for prompting the recycled, and does not work normally as a result, damage in the nerve cells and protein deposition, resulting in significant destruction of the nerve cells is called.
Ubiquitin 2 belongs to the finger giraffe family members, 1 other yubikirin yubikirin 2, 3 yubikirin, known yubikirin 4. Patent Document 1 and the 2, 1 yubikirin prostate cancer, lung cancer, or breast tumor antigen can be used as shown. To Patent Document 3, a tumor, cancer, neoplastic and malignant tumor hyperproliferative or aberrant cell proliferation or toxic method for treating a disease which is, as its target cell yubikirin cells expressing 1 are illustrated. In addition, in Patent Document 4, for detecting a predisposition to the onset of colorectal cancer as a measure of the method, the amount of expression of 4 yubikirin is disclosed. To Patent Document 5, the binding activity and topoisomerase II yubikirin inhibiting activity of small molecule anti-cancer agent as active ingredients disclosed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NARA MEDICAL UNIVERSITY
  • 発明者(英語)
  • KONISHI, Noboru
  • SHIMADA, Keiji
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close